The manufacture of TREG preparation begins with the collection of a venous blood sample of the patient under the care of the treating physician.
Treatment is carried out according to the following schedule:
The therapy is autologous, so the donor of blood and recipient of the finished product is one and the same person. Cells are not subjected to genetic manipulation, only their quantity – naturally low or less active in patients with type 1 diabetes – is multiplied under laboratory conditions, before being re-transfused.
The therapy is conducted at the University Clinical Centre in Gdańsk in the “Hospital Exemption” model, with full support of the hospital facilities with the highest purity laboratory in compliance with the GMP standard.